<DOC>
	<DOC>NCT00543075</DOC>
	<brief_summary>To characterize the pharmacokinetics of G3139 in subjects with normal, mildly impaired, and moderately impaired renal function who receive Genasense 3 mg/kg/day by continuous intravenous infusion for 2 days (48 hours).</brief_summary>
	<brief_title>Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Key inclusion criteria: Age &gt; 18 years Adequate organ function as determined &lt; 7 days prior to starting study medication (except for renal function, as specified per protocol) Creatinine clearance &gt; 80 mL/min based on the CockcroftGault formula for subjects in Group 1; or 50 to less than or equal to 80 mL/min based on the CockcroftGault formula and confirmed based on measured creatinine clearance for subjects in Group 2; or 30 to 49 mL/min based on the CockcroftGault formula and confirmed based on measured creatinine clearance for subjects in Group 3 Key exclusion criteria: Significant medical disease Prior organ allograft Coexisting condition that would require the subject to continue therapy during the treatment (infusion) phase of the study with a drug known to alter renal function</criteria>
	<gender>All</gender>
	<minimum_age>18 Weeks</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Renal Function</keyword>
	<keyword>Adult</keyword>
	<keyword>Genasense</keyword>
	<keyword>oblimersen</keyword>
	<keyword>G3139</keyword>
	<keyword>Genta</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>